文献速递胃肠外科围术期管理与 ERAS

细胞减灭术联合腹腔热灌注化疗中液体管理与并发症的关联

Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
PubMed 文献 · JAMA Surg · 2017-01-01

该回顾性研究分析了133例接受细胞减灭术联合腹腔热灌注化疗的腹膜癌患者,发现术中液体输注速率是综合并发症指数升高的独立预测因素,输注速率高于均值者并发症指数增加43%。

要点

  • 术中液体输注速率是CRS/HIPEC术后并发症的独立预测因素。
  • 液体输注速率高于均值者综合并发症指数增加43%。
  • 标准化限制性液体方案可能有助于减少CRS/HIPEC术后并发症。

核心结论

  • 术中液体输注与CRS/HIPEC患者围术期并发症显著增加相关。

研究设计与样本

  • 回顾性分析前瞻性机构数据库,纳入2009年4月15日至2016年6月23日133例原发或继发腹膜癌患者。

主要发现

  • 多因素分析显示年龄、术中液体输注速率和估计出血量是综合并发症指数升高的独立预测因素。
  • 术中液体输注速率高于均值者综合并发症指数为31.5,低于均值者为22.0,增加43%(P=0.02)。

关键数值与推荐

  • 术中液体输注速率均值15.7 mL/kg/h(IQR 11.3-18.7)。
  • 综合并发症指数均值26.0(IQR 8.7-36.2)。
  • 术中液体输注速率系数0.97(95%CI 0.19-1.75,P=0.02)。

临床怎么用

  • 在CRS/HIPEC中应考虑采用标准化限制性液体输注方案以降低并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal cancers can be associated with significant complications. Randomized trials have demonstrated increased morbidity with liberal fluid regimens in abdominal surgery. OBJECTIVE: To investigate the association of intraoperative fluid administration and morbidity in patients undergoing CRS/HIPEC. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis of information from a prospectively collected institutional database was conducted at a National Cancer Institute-designated comprehensive cancer center. A total of 133 patients from April 15, 2009, to June 23, 2016, with primary or secondary peritoneal cancers were included. EXPOSURES: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. MAIN OUTCOMES AND MEASURES: Morbidity associated with intraoperative fluid management calculated by the comprehensive complication index, which uses a formula combining all perioperative complications and their severities into a continuous variable from 0 to 100 in each patient. RESULTS: Of the 133 patients identified, 38% and 37% had diagnoses of metastatic appendiceal and colorectal cancers, respectively. Mean age was 54 (interquartile range [IQR], 47-64) years, and mean peritoneal cancer index was 13 (IQR, 7-18). Mitomycin and platinum-based chemotherapeutic agents were used in 96 (72.2%) and 37 (27.8%) of the patients, respectively. Mean intraoperative fluid (IOF) rate was 15.7 (IQR, 11.3-18.7) mL/kg/h. Mean comprehensive complication index (CCI) was 26.0 (IQR, 8.7-36.2). On multivariate analysis, age (coefficient, 0.32; 95% CI, 0.01-0.64; P = .04), IOF rate (coefficient, 0.97; 95% CI, 0.19-1.75; P = .02), and estimated blood loss (coefficient, 0.02; 95% CI, 0.01-0.03; P = .002) were independent predictors of increased CCI. In particular, patients who received greater than the mean IOF rate experienced a 43% increase in the CCI compared with patients who received less than the mean IOF rate (31.5 vs 22.0; P = .02). CONCLUSIONS AND RELEVANCE: Intraoperative fluid administration is associated with a significant increase in perioperative morbidity in patients undergoing CRS/HIPEC. Fluid administration protocols that include standardized restrictive fluid rates can potentially help to mitigate morbidity in patients undergoing CRS/HIPEC.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Eng OS, Dumitra S, O'Leary M, et al. Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy. JAMA Surg. 2017. PMID: 28832866. doi:10.1001/jamasurg.2017.2865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。